NCT03548155View on ClinicalTrials.gov

Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia

NACompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

July 24, 2014

Primary Completion Date

December 14, 2015

Study Completion Date

May 8, 2017

Conditions
SchizophreniaTherapeutics
Interventions
DRUG

Berberine

Berberine 300mg（three times a day） plus any atypical antipsychotic drug

DRUG

atypical antipsychotic

Any atypical antipsychotic drug as the basic treatment

DRUG

placebo

The placebo were matched to Berberine in shape, smell and colour and capsules were sealed in identical bottles

All Listed Sponsors
lead

Tianjin Anding Hospital

OTHER

NCT03548155 - Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter